Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
The CEO of Diagnostic Medical Systems S.A. (EPA:DGM) is Jean-Paul Ansel. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Next, we'll consider growth that the business demonstrates. Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. The aim of all this is to consider the appropriateness of CEO pay levels.
Check out our latest analysis for Diagnostic Medical Systems
How Does Jean-Paul Ansel's Compensation Compare With Similar Sized Companies?
According to our data, Diagnostic Medical Systems S.A. has a market capitalization of €18m, and pays its CEO total annual compensation worth €257k. (This figure is for the year to December 2017). We think total compensation is more important but we note that the CEO salary is lower, at €238k. We took a group of companies with market capitalizations below €179m, and calculated the median CEO total compensation to be €138k.
As you can see, Jean-Paul Ansel is paid more than the median CEO pay at companies of a similar size, in the same market. However, this does not necessarily mean Diagnostic Medical Systems S.A. is paying too much. We can better assess whether the pay is overly generous by looking into the underlying business performance.
You can see, below, how CEO compensation at Diagnostic Medical Systems has changed over time.
Is Diagnostic Medical Systems S.A. Growing?
Over the last three years Diagnostic Medical Systems S.A. has shrunk its earnings per share by an average of 15% per year (measured with a line of best fit). Its revenue is down -22% over last year.
Unfortunately, earnings per share have trended lower over the last three years. And the fact that revenue is down year on year arguably paints an ugly picture. So given this relatively weak performance, shareholders would probably not want to see high compensation for the CEO. We don't have analyst forecasts, but shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.
Has Diagnostic Medical Systems S.A. Been A Good Investment?
Given the total loss of 44% over three years, many shareholders in Diagnostic Medical Systems S.A. are probably rather dissatisfied, to say the least. So shareholders would probably think the company shouldn't be too generous with CEO compensation.
In Summary...
We compared total CEO remuneration at Diagnostic Medical Systems S.A. with the amount paid at companies with a similar market capitalization. Our data suggests that it pays above the median CEO pay within that group.